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Abstract
Introduction: Inflammation and coagulation are closely linked, and both can be triggered by endotoxin.
Thrombelastometry and impedance aggregometry are of diagnostic and predictive value in critically ill patients. In
this observational study we investigated the correlation of endotoxin activity with thrombelasometric and
aggregometric variables in patients with systemic inflammation.
Methods: Based on a daily screening on a tertiary academic surgical ICU, patients, as soon as they fulfilled two or
more criteria for systemic inflammatory response syndrome (SIRS), were included. In whole blood we performed
endotoxin activity (EA) assay, thrombelastometry (ROTEM®) and impendance aggregometry (Multiplate®).
Results: In total, 49 patients were included with a broad spread of EA levels of (median (minimum to maximum))
0.27 (0.01 to 0.72), allowing expedient correlative analysis. Clot formation time (CFT) (263 s (60 to 1,438 s)) and
clotting time (CT) (1,008 s (53 to 1,481 s)) showed a significant negative correlation with EA level (r = -0.38 (P <
0.005) and r = -0.29 (P < 0.05)). Positive correlations were found for alpha-angle (50° (17 to 78°), r = 0.40 (P <
0.005)) and maximum clot firmness (MCF) (55 mm (5/76), r = 0.27 (P < 0.05)). No significant correlations were
found between Lysis Index at 60 minutes (LI60) and EA levels. There was no correlation between EA level and
aggregometric values, or classical coagulation parameters.
Conclusions: In patients with systemic inflammation, increasing endotoxin concentrations correlate with increased
clot formation.
Introduction
During systemic inflammation, endotoxin (lipopolysac-
charide (LPS)), can originate from invading Gram-nega-
tive bacteria and/or translocation of endogenous Gram-
negative wall fragments. Translocation of endotoxin
appears in the context of gastrointestinal hypoperfusion
and gut failure, a frequently observed pathophysiology
on intensive care units [1]. Subsequently, LPS is released
into sterile compartments of the organism and in turn is
detected by pattern recognition receptors (PRRs), like
toll-like receptor (TLR)4, resulting in initiation of
inflammation and coagulation [2,3]. In critically ill
patients, concentrations of endotoxins are elevated and
measurable with the endotoxin activity (EA) assay. EA
levels correlate with Acute Physiology and Chronic
Health Evaluation II (APACHE II), the presence of
severe sepsis and mortality [4].
The cross-talk between inflammation and coagulation
is a central player in the pathophysiology of systemic
inflammation and sepsis [5,6]. In vitro and in vivo mod-
els demonstrate the potential of LPS to initiate clotting.
Added to whole blood, LPS reduces clotting time (CT)
as measured with (rotational) thrombelastometry (TEM)
[7,8]. Compared to healthy controls, both postoperative
patients and patients with sepsis demonstrate shorter
CTs and clot formation times (CFTs) [9]. In septic
patients, particularly CFT seems to correlate well with
clinical condition and outcome [10].
Furthermore, systemic inflammation alters platelet func-
tion, and under certain conditions, sepsis can lead to acti-
vation and aggregation of platelets [11-13]. However, more
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recent data demonstrate reduced platelet aggregation in
patients with severe sepsis compared to postoperative
patients [14]. The Multiplate® analyzer is a modern type
of impedance aggregometer which is designed as a bedside
tool (point of care) to assess platelet function [15].
The correlation between EA levels and thrombelasto-
metric or aggregometric measurements during systemic
inflammation has not been evaluated yet. The further
understanding of the relationship of systemic inflamma-
tion and coagulation in patients might be of relevance
for the introduction of new therapeutic approaches. For
example, endotoxin neutralizing or eliminating concepts
could also positively influence coagulatory dysregula-
tions in these patients.
The primary outcome of this prospective observational
study was the association of EA level and CFT in
patients with early systemic inflammation. Secondary
outcomes were the association of EA levels with further
thrombelastometric and aggregometric measurements
and the influence of infection (that is, sepsis).
Materials and methods
Patients
This single center prospective observational study
included adult patients with two or more systemic
inflammatory response syndrome (SIRS) criteria on a
26-bed tertiary academic surgical ICU. The study was
approved by the local ethical review committee (Univer-
sity Hospital Frankfurt, Germany) and carried out in
compliance with the principles established in the Hel-
sinki Declaration. Written informed consents were
obtained from the patients or legal representatives for
patients unable to consent. From April to July 2011, on
a daily basis between 06:30 to 07:30 am, all patients
were screened for SIRS criteria [16]. Patients fulfilling
two or more of the following SIRS criteria were
included: (a) core temperature of >38°C or <36°C, (b)
heart rate of >90 beats/minute, (c) respiratory rate of
>20 breaths/minute or partial pressure of arterial carbon
dioxide (PaCO2) <32 mmHg (all patients screened were
breathing spontaneously), (d) total WBC absolute count
>12,000 cells/mm3 or <4,000 cells/mm3. Sepsis was diag-
nosed when additionally, microbiological results revealed
an organism grown in blood/sterile sites or infected tis-
sue was detected clinically (for example, pneumonia).
Exclusion criteria: age <18 years, denial of informed
consent, chronic liver disease, treatment with anticoagu-
lants other than heparin or low molecular weight heparin
(LMWH), history of coagulopathy or thrombophilia.
Procedures
Demographic variables, routine blood tests, including
conventional clotting, clinical and microbiological data
were collected. Blood samples were obtained between
08:00 a.m. and 12:00 p.m. (noon) on the day of inclu-
sion. Inclusion bias was avoided by including patients
before measurements were performed. Blood samples
were drawn from an indwelling arterial line (flush setups
were not heparinised) and consisted of one EDTA-, one
citrate-tube and one heparinised tube, for EA, thrombe-
lastometric, and aggregometric measurements, respec-
tively. Measurements were performed within one hour.
EA levels were determined by Endotoxin Activity Assay
(EAA) (EAA™, Spectral Diagnostics Inc., Toronto, ON,
Canada), according to the manufacturer’s instruction.
Rotational thromboelastometry measurements were per-
formed according to the manufacturer’s recommenda-
tions (ROTEM®, Tem International GmbH, München,
Germany). A total of 300 μL of citrated blood was
pipetted into ROTEM® sample cups and heparinase (to
exclude potential effects of heparin) and CaCl2 (20 μl
heparinase and 0.2 M CaCl2, NATEM-test) were added.
The NATEM-test was chosen since no activators are
added. In vitro experiments revealed that endotoxin
initiated clotting activation cannot be measured suffi-
ciently by thrombelastometry when performed with
additional clotting activators [7]. Furthermore, the
NATEM-test has been previously evaluated in patients
with systemic inflammation [9,10]. Sample tubes were
temperature controlled at 37°C. CT, CFT, maximum
clot firmness (MCF), alpha angle and 60-minute lyses
index (LI60) were determined. Platelet function was
investigated by impedance aggregometry using Multi-
plate® (Verum Diagnostica GmbH, Munich, Germany)
analysis according to the manufacturer´s recommenda-
tions. A total of 300 μl heparinised whole blood and 300
μl saline was pipetted into the test cells which were
temperature controlled at 37°C. Samples were activated
with arachidonic acid (ASPI), adenosine diphosphate
(ADP), or thrombin receptor activating peptide 6
(TRAP). Results are given as area under curves of arbi-
trary aggregation units (A.U.) over time.
Statistical analysis
Statistical analyses were performed with Prism® 5.02
(GraphPad Software, San Diego, CA, USA). The correla-
tion of EA activity units with viscoelastic (ROTEM®) and
aggregometric (Multiplate®) parameters were analyzed
by Spearmann’s correlation test. Groups were compared
using the Mann-Whitney U or Kruskal-Wallis (followed
by Dunn’s multiple comparison) test for continuous vari-
ables and chi-square tests for categorical variables. P <
0.05 was regarded as statistically significant.
Results
A total of 49 patients, all European Caucasians, fulfilled
the inclusion criteria during the observation period.
Characteristics are given in Table 1. Patients were
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admitted following trauma, major surgical procedures or
for postoperative complications, such as respiratory fail-
ure or resuscitation. The median (minimum-maximum)
length of stay on ICU before inclusion was 2 (0 to 58)
days. In 33 patients infection was present at the time of
inclusion. The primary site of infection was the lung,
followed by the abdomen. In one patient the blood cul-
ture was positive. Other infection sites included muscle
tissue or the urinary tract (Table 1). Thrombosis pro-
phylaxis was provided with heparin-infusion in 29
(59.2%) or low molecular weight heparin (LMWH) in 13
(26.5%) patients. Seven (14.3%) patients did not receive
thrombosis prophylaxis. The median (minimum-maxi-
mum) heparin-infusion rates were 400 (200 to 1,000)
units/h. LMWHs included enoxaparin (n = 6) 70 (40 to
120) mg/d, nadroparin-calcium (n = 2) 5,700 (3,800 to
7,600) units/d and dalteparin (n = 5) 10,000 (10,000 to
10,000) units/d. Fourteen (28.6%) patients received anti-
platelet therapy (acetylsalicylic acid, 100 mg/d).
Patients with SIRS or sepsis did not differ significantly
in age, sex, body mass index (BMI), SIRS criteria, type
of anticoagulation, Acute Physiology and Chronic Health
Evaluation (APACHE) II or Simplified Acute Physiology
Score (SAPS) II.
EA and viscoelastic ROTEM® variables
EA levels showed a broad distribution with a median
(minimum-maximum) of 0.27 (0.01 to 0.72). In two
patients, thrombelastometric measurements failed for
technical reasons. The median values (minimum-maxi-
mum) of the viscoelastic variables were CFT: 263 s (60 to
1,438 s), CT: 1,008 s (53 to 1,481 s), and alpha-angle: 50°
(17 to 78°). The primary outcome of this study, that is, the
association of EA and CFT, showed a significant negative
correlation (r = -0.38, P < 0.005) (Figure 1). Furthermore,
a negative correlation was found for CT (r = -0.29,
P < 0.05), a positive correlation was found for alpha-angle







Age† 70 (28/87) 71.5 (53/86) 70 (28/87)
Male‡ 35 (71.4) 11 (68.8) 24 (72.7)
BMI† 27.1 (16.3 to 40.4) 27.5 (20.8 to 27.0) 26.3 (16.3 to 40.4)
Infection‡ 33 (67.4) 0 (0) 33 (100)
Infection site See sepsis NA Lung: 17
NA Abdominal: 8
NA Positive blood culture: 1
NA Other: 7
Temperature (°C)† 36.4 (33.4 to 38.9) 36.5 (35.2 to 38.0) 36.4 (33.4 to 38.9)
Heart rate (bpm)† 90 (60 to 140) 90 (70 to 100) 90 (60 to 140)
Respiratory rate (c/min)† 15 (10 to 29) 15.5 (11 to 21) 15 (10 to 29)
Leukocytes (×109/L)† 14.4 (2.5 to 48.0) 13.6 (7.1 to 28.8) 15.0 (2.5 to 48.0)
Anticoagulation‡ Heparin: 29 (59.2) 7 (43.8) 22 (66.7)
LMWH: 13 (26.5) 6 (37.5) 7 (21.2)
None: 7 (14.3) 3 (18.8) 4 (12.1)
APACHE II 16 (5 to 29) 16 (10 to 26) 16 (5 to 29)
SAPS II 46 (19 to 90) 43 (24 to 62) 48 (19 to 90)
†, median (minimum-maximum); ‡, n (%); APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; bpm, beats per minute; LMWH, low
molecular weight heparin; SAPS, Simplified Acute Physiology Score; SIRS, systemic inflammatory response syndrome
Figure 1 Endotoxin activity (EA) and NATEM clotting formation
time (CFT). r, Spearman’s correlation coefficient
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(r = 0.40, P < 0.005) (Figures 2 and 3). A positive correla-
tion could also be observed for maximum clot firmness
(MCF). No correlations were found between EA and Lysis
Index at 60 minutes (LI60) (Table 2). Viscoelastic para-
meters did not differ significantly between patients
receiving heparin-infusion, LMWH or no antithrombosis
prophylaxis (data not shown).
EA and aggregometric Multiplate® variables
No significant relations were found between EA and ASPI-
test, ADP-test or TRAP-test (Table 2). Aggregometric
parameters and correlations to EA were not influenced
significantly by antiplatelet therapy (data not shown).
EA and conventional clotting variables
No significant correlations were found between EA and
platelet count, International Normalized Ratio (INR),
activated Partial Thromboplastin Time (aPPT), fibrino-
gen concentration, thrombin time or antithrombin activ-
ity (Table 2).
SIRS versus sepsis
EA activity, thrombelastometric, aggregometric or con-
ventional clotting parameters did not differ significantly
between SIRS and sepsis patients (Table 3).
Discussion
In this prospective observational study we investigated
the relation between systemic endotoxin levels and clot-
ting dynamics. We found EA levels to negatively corre-
late with CFT and CT. Positive correlations were found
for alpha-angle and MCF, indicating that clot formation
was faster and firmer when EA levels were higher. We
did not observe any effect of EA levels on LI60, that is,
clot lyses. Furthermore, there was no correlation
Figure 2 Endotoxin activity (EA) and NATEM clotting time (CT).
r, Spearman’s correlation coefficient
Figure 3 Endotoxin activity (EA) and NATEM alpha-angle. r,
Spearman’s correlation coefficient
Table 2 Thrombelastometric and aggregometric findings,
conventional clotting variables
Variables Value Correlation with EA
r P
CFT (sec) 263 (60 to 1,438) -0.38 <0.005
CT (sec) 1,008 (53 to 1,481) -0.29 <0.05
Alpha angle (°) 50 (17 to 78) 0.40 <0.005
MCF (mm) 55 (5 to 76) 0.27 <0.05
LI60 (60%) 98 (90 to 100) -0.04 NS
ASPI (AUC (AU*min)) 697 (53 to 1,481) 0.01 NS
ADP (AUC (AU*min)) 518 (18 to 1,176) 0.01 NS
TRAP (AUC (AU*min)) 818 (122 to 1,831) -0.05 NS
Platelets (×109/L) 145 (17 to 523) 0.02 NS
INR 1.39 (1.04 to 3.58) 0.01 NS
APPT (sec) 45 (32 to 112) 0.02 NS
Thrombin time (sec) 16.5 (14.0 to 95.0) -0.11 NS
Fibrinogen (mg/dL) 440 (60 to 1,106) -0.10 NS
Antithrombin (%) 62 (27 to 90) -0.08 NS
ADP, adenosine diphosphate activated aggregometric analysis; aPPT, activated
partial thromboplastin time; median (minimum-maximum); ASPI, arachidonic
acid activated aggregometric analysis; CFT, clotting formation time; CT,
clotting time; INR, international normalized ratio; LI60, 60-minute lyses index;
MCF, maximum clot firmness; TRAP, thrombin receptor activating peptide 6
activated aggregometric analysis
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between EA levels and platelet function, as investigated
by aggregometric measurements (ASPI-, ADP-, TRAP-
test). Also, conventional clotting tests (platelet count,
INR, aPPT, thrombin time) or clotting factor measure-
ments (fibrinogen, antithrombin) did not correlate with
EA levels. There were no differences in EA levels,
thrombelastometric, aggregometric or conventional clot-
ting parameters between SIRS and sepsis patients.
SIRS following major surgery (for example, heart sur-
gery, liver transplantations), burns or major trauma is
associated with increased endotoxin blood levels
[17-24]. It is thought that endotoxin translocates in the
context of gastrointestinal hypoperfusion and gut failure.
Thereby, EA in the blood seems to mainly reflect organ
dysfunction with regard to the integrity of the gut,
which can be observed in patients with SIRS, Gram
positive or Gram negative sepsis [25,26]. In patients
with systemic inflammation caused by infection, that is,
sepsis, EA levels tend to be higher. However, we and
others showed that EA levels do not discriminate
between SIRS and sepsis [4]. With the intention of mea-
suring a broad range of EA levels, we defined the pre-
sence of two SIRS criteria as inclusion criteria,
regardless of cause or severity of systemic inflammation.
EA levels can be graduated into low (<0.4), intermediate
(0.40 to 0.59) and high (≥0.6). The range of EA levels
we observed are slightly lower, however, of a compar-
able broad spread when compared to the MEDIC study
[4]. This allowed us to correlate various EA levels with
corresponding thrombelastographic and aggregometric
parameters. The fact that we observed lower EA levels
compared to the MEDIC study could be due to differ-
ences in inclusion times. While all patients of the
MEDIC study were included within 24 h, the median
inclusion time in our study was 2 d after ICU admission.
One could speculate that in our population initial stabi-
lisation following, for example, surgery was more
advanced, and surgery related endotoxin release was of
reduced impact.
In 33 patients, SIRS was associated with infection,
resulting in sepsis, severe sepsis or septic shock. Our
analysis did not discriminate between the different
grades of sepsis, as this would result in small group
numbers. Furthermore, we aimed to investigate the
mere effect of EA on thrombelastographic and aggrego-
metric parameters, rather than trying to detect differ-
ences between groups to which patient allocation often
is difficult.
TLR activation results in the intracellular activation of
NF-B and the subsequent release of various cytokines,
nitric oxide, several other mediators and tissue factor
(TF) [5,27]. Circulating TF is released primarily by acti-
vated monocytes, granulocytes and macrophages. Var-
ious conditions, including SIRS and sepsis, are related to
increased TF levels [28,29]. The central role of TF in
systemic inflammation could be demonstrated by block-
ing TF in Escherichia coli-induced septic shock, which
increased survival in an animal model [30]. In human
volunteers, the injection of LPS leads to a fast increase
of TF mRNA in monocytes [31]. TF activates the TF/
FVIIa pathway, activating FIX and FX, resulting in
thrombin formation [32]. On the other hand, anticoagu-
latory mediators like antithrombin, protein C and S
levels are decreased during systemic inflammation, sup-
porting the procoagulatory state of the clotting system
[33,34].
In in vitro and animal experiments as well as in
healthy subjects, clotting activation by endotoxin could
be observed [7,35,36]. In healthy volunteers, low dose
endotoxin, compared to placebo, reduces CT, but does
not affect CFT or MCF [8]. Thrombelastometric obser-
vations performed with NATEM-tests in patients with
severe sepsis demonstrate that compared to healthy con-
trols, MCF and alpha-angle were increased, that is, clot
formation was firmer [37]. Also performing the
NATEM-test, Adamzik et al. observed a shorter CT and
CFT, and a higher alpha-angle in septic patients com-
pared to healthy probands [9]. As severe sepsis is asso-
ciated with high EA levels, these results would be in line
with our findings. However, some further, earlier studies
with ROTEM® in patients with severe sepsis or septic
shock are difficult to interpret and probably not
Table 3 EA, thrombelastometric and aggregometric
findings, conventional clotting variables in SIRS and
sepsis patients
SIRS Sepsis
Variables Value Value P
EA 0.27 (0.14 to 0.52) 0.27 (0.01/0.72) NS
CFT (sec) 263 (150 to 1,438) 268 (60/942) NS
CT (sec) 906 (648 to 1,380) 1027 (53 to 1,481) NS
Alpha-angle (°) 50 (24 to 69) 47 (17 to 78) NS
MCF (mm) 53 (24 to 67) 57 (5 to 76) NS
LI60 (60%) 98 (90 to 100) 99 (93 to 100) NS
ASPI (AUC (AU*min)) 506 (49 to 1,137) 772 (21 to 1,667) NS
ADP (AUC (AU*min)) 539 (125 to 804) 504 (18 to 1,176) NS
TRAP (AUC (AU*min)) 799 (339 to 1,494) 887 (122 to 1,831) NS
Platelets (×109/L) 131 (61 to 257) 166 (17 to 523) NS
INR 1.40 (1.14 to 3.58) 1.37 (1.04 to 2.12) NS
APPT (sec) 44 (38 to 112) 45 (32 to 79) NS
Thrombin time (sec) 17 (14 to 95) 16 (14 to 79) NS
Fibrinogen (mg/dL) 392 (60 to 829) 451 (112 to 1,106) NS
Antithrombin (%) 57 (31 to 90) 62 (27 to 88) NS
ADP, adenosine diphosphate activated aggregometric analysis; aPPT, activated
partial thromboplastin time; median (min-max); ASPI, arachidonic acid
activated aggregometric analysis; CFT, clotting formation time; CT, clotting
time; EA, endotoxin activity; INR, international normalized ratio; LI60, 60-
minute lyses index; MCF, maximum clot firmness; TRAP, thrombin receptor
activating peptide 6 activated aggregometric analysis
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comparable with our findings [12,38]. This is because
clotting activators were used (INTEM, EXTEM and so
on). ROTEM® analysis working with clotting activators,
such as the INTEM- or the EXTEM-test, might not be
sensitive enough to detect clotting abnormalities caused
by systemic inflammation/infection. For example, the
EXTEM-test uses TF as an activator. As TF is thought
to be a central player during inflammatory induced clot-
ting, using it as an activator might override the effects
we aimed to investigate. In our study, we omitted activa-
tors by using the NATEM-test with heparinase only.
Furthermore, the inclusion time in previous trials often
was not focused on early systemic inflammation, but on
established sepsis. With the inclusion criteria severe sep-
sis or septic shock, the inclusion time tends to be later
compared with the inclusion criteria SIRS, as microbiol-
ogy results often are essential for the diagnosis severe
sepsis and septic shock.
Recently, it was demonstrated that impedance aggre-
gometry has diagnostic and prognostic value in
patients with severe sepsis. Compared to post-surgical
patients, patients with severe sepsis showed reduced
platelet aggregation in the collagen-test, ADP-test, AA-
test and TRAP-test [14]. Our results did not show dif-
ferences in aggregometric variables between SIRS and
sepsis patients. This might be explained by the fact
that in SIRS patients, systemic inflammation can be
more severe than in post-surgical patients. Further-
more, the sepsis group in our study also included
patients with sepsis without organ dysfunction, that is,
a less severe form of sepsis compared to severe sepsis.
Therefore, in our patient groups (SIRS vs. sepsis) clini-
cally and inflammatory conditions were more contigu-
ous, which might explain the absence of differences in
our results. Another study, comparing post-surgical
with septic shock patients did not, with the exception
of ADP, find differences in aggregometric variables
(ASPI, COL, TRAP-test) [12]. Again, investigated
patient groups (post-surgical vs. septic shock) differed
from ours.
The absence of a correlation between EA levels and
conventional clotting parameters, as well as the fact that
the groups SIRS and sepsis did not differ in this regard,
is in line with previous observations. In septic patients,
platelet counts tend to be lower when compared to
healthy individuals, but not compared to post surgical
or SIRS patients [12,39]. Perioperative systemic endo-
toxin concentrations do not correlate with platelet
counts or aPPT [40,41]. Prothrombin time (PT) (in our
study represented by INR) does not differ between con-
trols, patients with sepsis or severe sepsis. Only in
patients with septic shock, a prolongation can be
observed [42]. Therefore, our results support the insight
that global clotting tests are not sensitive enough to
detect clotting derangements caused by systemic inflam-
mation, apart from extremes, such as septic shock.
This study focused on early SIRS and sepsis states.
With the progress of SIRS or sepsis, EA level and coagu-
lation courses over time become extremely complex by
the influence of various unbalanced pro- and anti-
inflammatory/pro- and anti-coagulatory mechanisms.
This is in line with our observations, which initially
included analysis for five consecutive days. With EA
levels and coagulatory variables following indefinable
courses, we focused on early stages of SIRS and sepsis.
Still, the correlations we found are not very intense.
This might reflect the above mentioned fast and diverse
dynamic of inflammatory and coagulatory processes,
whose exact onset cannot precisely be captured by a
screening resolution of 24 hours. Potentially, higher
numbers of patients would have adjusted this synchroni-
sation deficiency. Furthermore, medical histories and
clinical conditions of the patients were very heteroge-
neous, which should be considered when interpreting
the levels of correlation coefficients.
Conclusion
The impact of endogenously released endotoxin on clot-
ting has not been evaluated before. Here we demon-
strate a correlation between EA levels and viscoelastic
parameters, suggesting an in vivo link between endogen-
ous endotoxin concentrations and coagulation. With
increasing EA levels clot formation becomes faster and
firmer in patients with early systemic inflammation,
independent of cause (non-infectious or infectious) or
severity. With the development of endotoxin neutraliz-
ing therapeutic options, the further understanding of the
link between systemic inflammation and coagulation
might be of relevance [25].
Key messages
• In patients with early systemic inflammation,
increasing endotoxin concentration correlates with
faster and firmer clot formation.
• Neither platelet counts or function nor conven-
tional clotting parameters were influenced by endo-
toxin concentration.
• Patients with SIRS did not differ from patients
with sepsis in endotoxin concentrations, clot forma-
tion, platelet counts or function, or conventional
clotting parameters.
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